Next 10 |
Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019 Anticipate CE Mark in the first half of calendar 2020 Announced licensing agreement ...
AIT Therapeutics (NASDAQ: AITB ): Q4 GAAP EPS of -$0.49. More news on: AIT Therapeutics, Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019 Anticipate CE Mark in the first half of calendar 2020 Announced licensing agreeme...
GARDEN CITY, N.Y. and REHOVOT, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including s...
GARDEN CITY, N.Y. and REHOVOT, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including s...
GARDEN CITY, N.Y. and REHOVOT, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including s...
GARDEN CITY, N.Y. and REHOVOT, Israel, May 29, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including se...
GARDEN CITY, N.Y. and REHOVOT, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including se...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. No formal trade talks are scheduled between the U.S. and China, but President Trump...
News, Short Squeeze, Breakout and More Instantly...
AIT Therapeutics Inc Company Name:
AITB Stock Symbol:
OTCMKTS Market:
Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019 Anticipate CE Mark in the first half of calendar 2020 Announced licensing agreement ...
Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019 Anticipate CE Mark in the first half of calendar 2020 Announced licensing agreeme...
GARDEN CITY, N.Y. and REHOVOT, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including s...